Trials / Unknown
UnknownNCT02115152
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
Phase II Neoadjuvant Trial of Capecitabine, Cyclophosphamide and Epirubicin for Patients With Axillary Lymph Node Positive Stage II-III Operable Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Guangxi Medical University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fluorouracil | |
| DRUG | capecitabine | |
| DRUG | cyclophosphamide | |
| DRUG | Epirubicin |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2018-06-01
- First posted
- 2014-04-15
- Last updated
- 2014-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02115152. Inclusion in this directory is not an endorsement.